New York State Common Retirement Fund Lowers Stock Holdings in Bristol Myers Squibb Company (NYSE:BMY)

New York State Common Retirement Fund trimmed its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 0.4% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 2,532,336 shares of the biopharmaceutical company's stock after selling 9,100 shares during the period. New York State Common Retirement Fund owned about 0.12% of Bristol Myers Squibb worth $154,447,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in the stock. Norges Bank bought a new position in shares of Bristol Myers Squibb in the 4th quarter valued at about $1,989,525,000. Ameriprise Financial Inc. increased its holdings in Bristol Myers Squibb by 59.9% in the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in Bristol Myers Squibb by 701.2% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock worth $705,309,000 after acquiring an additional 10,913,708 shares during the period. Wellington Management Group LLP boosted its position in shares of Bristol Myers Squibb by 3,880.0% during the 4th quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock worth $338,088,000 after purchasing an additional 5,827,317 shares in the last quarter. Finally, Schroder Investment Management Group lifted its position in Bristol Myers Squibb by 49.7% in the 4th quarter. Schroder Investment Management Group now owns 11,413,428 shares of the biopharmaceutical company's stock valued at $639,837,000 after acquiring an additional 3,787,075 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on BMY shares. The Goldman Sachs Group restated a "neutral" rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Jefferies Financial Group decreased their price objective on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective on the stock. Finally, Morgan Stanley lowered their target price on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating on the stock in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $57.69.

Bristol Myers Squibb Trading Up 1.4%

NYSE:BMY traded up $0.64 during midday trading on Monday, hitting $47.50. The stock had a trading volume of 2,902,385 shares, compared to its average volume of 13,407,457. Bristol Myers Squibb Company has a one year low of $39.92 and a one year high of $63.33. The company has a market capitalization of $96.67 billion, a price-to-earnings ratio of 17.78, a PEG ratio of 2.38 and a beta of 0.36. The stock has a 50-day moving average of $47.51 and a 200 day moving average of $53.22. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The company had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter in the prior year, the firm earned ($4.40) earnings per share. Bristol Myers Squibb's revenue was down 5.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be given a dividend of $0.62 per share. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.22%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Insider Transactions at Bristol Myers Squibb

In other news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction on Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president owned 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.09% of the stock is owned by company insiders.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.